Navigation Links
New hope in the fight against childhood cancer
Date:7/11/2013

Researchers in the Antibody and Vaccine Group have developed two monoclonal antibodies (mAbs) called anti-4-1BB and anti-CD40 and investigated a third called anti-CTLA-4. Each of these antibodies binds to a different target molecule in the immune system, potentially heightening the body's own immune response to cancer.

Published in the July edition of Clinical Cancer Research, the study has shown that the antibodies boost the immune system to fight neuroblastoma -- a form of childhood cancer which grows from undeveloped tissue of the nervous system.

They found that 40 to 60 percent of the tumours treated with the stimulatory antibodies regressed in the laboratory models and ensured long-term survival. With more aggressive tumours, the antibodies alone did not significantly slow tumour growth, however, when the researchers paired one of the monoclonal antibodies with a cancer vaccine called Survivin a similar survival benefit was seen.

Dr Juliet Gray, Senior Lecturer in Paediatric Oncology and Cancer Research UK scientist at the University of Southampton, comments: "Although this work is still at a pre-clinical stage, we hope it has enabled us to identify a way that we can provide effective immunotherapy treatment against neuroblastoma. More research is needed to understand how these antibodies work and how they should be used to treat neuroblastoma.

"Six out of ten children with neuroblastoma can be successfully treated with conventional chemotherapy. But for those children who don't respond well to this treatment, immunotherapy could become a vital new treatment option."

The body's immune response is generally much weaker to cancer than it is to infections, and in most cases it does not stop tumours from growing. The body holds anti-cancer cells called T-cells, but cancer has the ability to switch off or subdue the immune recognition in these cells.

The antibodies are engineered to wake the T-cells up from their slumber and thereby restore the anti-cancer activity to attack the tumour. This process is already being used in adult trials for a range of cancers including skin, head and neck and pancreatic cancer. This pre-clinical data will allow Dr Gray and her team to design the first peadiatric clinical trials.

Dr Gray, who is also a paediatric oncologist at Southampton General Hospital, adds: "Neuroblastoma affects around 100 children in the UK each year with most cases being diagnosed under the age of five. It is a serious disease but we need to be clear about how to move forward with it. There are a number of things that make conducting a clinical trial in children very challenging. Therefore, it is important that we learn as much as we can in the lab, in advance of a clinical trial, about how this type of therapy can be best used in childhood cancers."

Cancer Research UK scientist, Professor Martin Glennie, Head of the Cancer Sciences at the University of Southampton, who also worked on the study, says: "We very much hope these results will enable us to develop a pioneering immunotherapy treatment for a childhood cancer. In theory this approach enables us to kill cancer cells without damaging healthy cells, resulting in fewer toxic side effects such as hair loss, nausea and tiredness.

"The next stage of our work will be to see if the treatment is a safe and effective treatment for children and also seek to understand how these antibodies can be used in combination with other treatments to maximise their effect."


'/>"/>

Contact: Becky Attwood
r.attwood@soton.ac.uk
44-023-805-95457
University of Southampton
Source:Eurekalert

Related medicine news :

1. Eliminating the good cholesterol receptor may fight breast cancer
2. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
3. From a Failed Vaccine, New Insights Into Fighting HIV
4. Doctors Detail High Costs of Fighting Malpractice Claims
5. How does the immune system fight off threats to the brain? New research yields fresh insight
6. Exercise Can Help Fight Heart Failure
7. Scripps Research scientists show how memory B cells stay in class to fight different infections
8. Southeast program to fight diabetes awarded nearly $10 million by HHS
9. Soybeans soaked in warm water naturally release key cancer-fighting substance
10. Living longer - variability in infection-fighting genes can be a boon for male survival
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , ... dental care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments ... are at risk for serious complications and often experience severe pain. Not only ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that ... gift was facilitated by the Pepin Family Foundation. , “We greatly appreciate this ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your ... care, and MEDfx and the Delaware Health Information Network (DHIN) have partnered to ... nation’s first state-wide health information exchange, DHIN stores and shares real-time health data ...
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... Butler Mobility ... the Stannah Stairlift and other Butler products. Ken was impressed with the safety ... agreed to endorse the product on his show. This endorsement by Ken Matthews ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 2017 Acute, Chronic and Prophylaxis GVHD ... a CAGR of 7% from 2016-2021 and CAGR of 3% from 2021-2027. ... 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn ... ... how you can exploit the future business opportunities emerging in this sector. ...
(Date:2/19/2017)... 19, 2017  nThrive™, an independent Patient-to-Payment? solutions ... thought leadership at the 2017 HIMSS Conference. The ... award from KLAS. nThrive will host ... how market trends shape the holistic, integrated revenue ... comprehensive Patient Access solution. The panel will reveal ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
Breaking Medicine Technology: